The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
 
Susan Halabi
Employment - ASCO
Honoraria - AVEO; Bristol-Myers Squibb; Janssen; Sanofi
 
Siyuan S Guo
No Relationships to Disclose
 
Akash Roy
No Relationships to Disclose
 
Larysa Rydzewska
No Relationships to Disclose
 
Peter Godolphin
No Relationships to Disclose
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; AstraZeneca; AstraZeneca; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Precisca; Targeted Oncology; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Pfizer; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Catherine Tangen
No Relationships to Disclose
 
Ian Thompson
Leadership - H-E-B (grocery store chain)
Consulting or Advisory Role - Magforce
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Wanling Xie
Consulting or Advisory Role - Convergent Therapeutics
 
Michael Anthony Carducci
Consulting or Advisory Role - Acrivon Therapeutics; AstraZeneca; Pfizer; Sanofi
Speakers' Bureau - Remedica
Research Funding - Arcus Biosciences (Inst); Celgene/Bristol-Myers Squibb (Inst); Merck (Inst); pfizer (Inst)
 
Matthew Raymond Smith
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen Oncology; Lilly; Novartis; Pfizer
Research Funding - Bayer (Inst); ESSA (Inst); Janssen Oncology (Inst); Lilly (Inst); ORIC Pharmaceuticals (Inst)
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Amgen; AstraZeneca; Clarity Pharmaceuticals; Convergent Therapeutics; Daiichi; Exelixis; ITM Isotope Technologies Munich; Lantheus Medical Imaging; NCCN; Pfizer
Research Funding - Bayer (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst); Progenics (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer; Janssen Oncology; Novartis
 
Gwenaelle Gravis
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); BMS (Inst); Curium Pharma (Inst); Janssen (Inst); Merck/Pfizer (Inst)
Speakers' Bureau - Advanced Accelerator Applications (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst)
Research Funding - BMS (Inst)
Expert Testimony - BAYER (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Pfizer
 
David P. Dearnaley
Consulting or Advisory Role - Janssen Oncology
Patents, Royalties, Other Intellectual Property - Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. Professor Dearnaley is on the Institute’s Rewards to Inventors list for abiraterone acetate. (Inst); Patent issued EP1933709B1 (location and stabilisation device)
 
Paul Verhagen
No Relationships to Disclose
 
Takayuki Goto
No Relationships to Disclose
 
Nicholas D. James
No Relationships to Disclose
 
Mahesh Parmar
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Janssen (Inst)
 
Marc E. Buyse
Employment - IDDI
Stock and Other Ownership Interests - IDDI
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination